What kava kava doses do regulators and studies give?

Strengths and daily limits
SourceStrengthDaily figure
TGA (Australia), 2002 alert1Kava-containing medicines: tablets and capsules up to 125 mg kavalactones; tea bags up to 3 g dried rhizomeNot more than 250 mg kavalactones a day, any dosage form
NSW Health3Capsule formulations 50 to 100 mg, for the majorityRecommended maximum daily dose 250 mg
Traditional use, NSW Health3Ground or chewed root750 to 8,000 mg kavalactones
2020 review, on US dietary supplements4Typically one to three capsules a day, for an adult60–250 mg kavalactones a day for one or two months
Cochrane review, as cited by a review4Symptomatic treatment of anxiety60–280 mg kavalactones a day

The TGA's 2002 practitioner alert gives a limit for kava-containing medicines of not more than 250 mg of kavalactones a day in any dosage form, in tablets or capsules of up to 125 mg each,1 while the 16-week phase III trial by Sarris and colleagues (2020) gave 120 mg twice a day to 171 participants with generalised anxiety disorder and found a non-significant difference in anxiety reduction between kava and placebo.2

Strengths and daily limits

The table is set at the top of the page

NSW Health adds that no toxic dose is well established.3 A DailyMed search for kava returned only a veterinary product, not a human label.

Doses used in human trials

TrialDose and schedulePeopleLength
Sarris 2013, aqueous kava5Aqueous kava extract, 120/240 mg kavalactones a day depending on response, versus placebo75 participants with GAD enrolled, 58 analysed6 weeks
Sarris 2020, phase III2Aqueous kava root extract tablets, 120 mg kavalactones twice a day, versus placebo171 participants with GAD16 weeks
KADSS, Sarris 20096Five tablets a day, 250 mg kavalactones a day, placebo-controlled crossover60 adults with 1 month or more of elevated generalized anxiety3 weeks
Sarris 2012, oxazepam crossover7One acute dose of 180 mg kavalactones, against oxazepam 30 mg and placeboTwenty-two moderately anxious adults aged 18 to 65Doses 1 week apart
NCT02219880, University of Melbourne8Planned 240 mg kavalactones a day, from 60 mg tablets, two tablets twice a day, versus placebo210 adults with GAD planned, 178 enrolled18 weeks planned
NCT045651459Three 75 mg kava capsules a day versus placebo39 adults with GAD enrolledOne week, then 12 weeks of follow-up

The NCT02219880 registry entry lists the 2020 Sarris paper among its references; the paper reports 16 weeks and 171 participants, the entry 18 weeks, 210 adults planned and 178 enrolled.28 The University of Florida pharmacokinetic study by Kanumuri and colleagues, in ten healthy volunteers aged 18 to 40 (the study admitted adults aged 18 to 50), gave one group a single 225 mg kavalactones dose and the other three times a day (3 × 75 mg) dosing, and observed higher exposure after the single dose and a longer duration of exposure with the three-times-a-day dosing.10

Preparing kava root powder

A 2020 review says the dried root is ground into a powder, mixed with ambient-temperature water or coconut milk and filtered through a cloth into a suspension.4 It gives water as the traditional solvent, with flavokavains A and B about 100 times higher in an ethanolic preparation than in an aqueous one.4

How long kava is used, and what not to mix with it

NCCIH says kava supplements may be helpful for anxiety but may need to be taken for several weeks to produce an effect, and that kava does not appear to be helpful for symptoms of generalized anxiety disorder.11 The Cochrane review says the data from its studies suggest kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required.12 For US kava dietary supplements, a 2020 review gives a typical adult daily dose of 60–250 mg kavalactones, as one to three capsules, for one or two months, and none of the pages searched states a cycle of weeks on and weeks off.4

NCCIH advises against using kava together with sedative substances such as benzodiazepines or alcohol.11 NSW Health says it may add to the effects of other central nervous system depressants, including alcohol.3 NCCIH reports rare cases of liver injury linked to kava products, some of them serious or even fatal, including cases from kava beverages prepared with water.11

Storage

A 2020 review lists storage conditions among the factors that could contribute to variations in kava composition, and the improper handling and storage of kava materials as one hypothesised cause of the liver cases, none of these proposals validated.4

Frequently asked questions

How is kava taken?

The pharmacokinetic study gave 75 mg kavalactone capsules orally.10 In that study's multiple-dose part, the extent of absorption of kavalactones was significantly reduced with food.10

How does a kava dose in mg become a volume or syringe mark?

None of the saved sources gives kava as a liquid or injection with a mg/mL concentration; they give tablet and capsule strengths of 60 and 75 mg kavalactones, a TGA limit of 125 mg kavalactones per tablet or capsule and a 3 g tea bag limit, so no syringe arithmetic applies.8101

What do Milligram users log for kava kava?

Milligram's report has no line for kava kava, so no logged share is given.

References

  1. TGA. Kava practitioner alert. tga.gov.au
  2. The Australian and New Zealand journal of psychiatry (PubMed abstract). Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. 2020. pubmed.ncbi.nlm.nih.gov
  3. NSW Health. Kava clinical factsheet. health.nsw.gov.au
  4. Journal article. Kava as a Clinical Nutrient: Promises and Challenges. 2020. pmc.ncbi.nlm.nih.gov
  5. Journal of clinical psychopharmacology (PubMed abstract). Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. 2013. pubmed.ncbi.nlm.nih.gov
  6. Psychopharmacology (PubMed abstract). The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. 2009. pubmed.ncbi.nlm.nih.gov
  7. Human psychopharmacology (PubMed abstract). The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. 2012. pubmed.ncbi.nlm.nih.gov
  8. ClinicalTrials.gov (US National Library of Medicine). NCT02219880: Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial. 2018. clinicaltrials.gov
  9. ClinicalTrials.gov (US National Library of Medicine). NCT04565145: Biomarker Changes and Anxiolytic Effects-Phase 2. 2024. clinicaltrials.gov
  10. Journal article. Clinical pharmacokinetics of kavalactones after oral dosing of standardized kava extract in healthy volunteers. 2022. pmc.ncbi.nlm.nih.gov
  11. NCCIH. Kava: Usefulness and Safety. nccih.nih.gov
  12. Journal article. Kava extract versus placebo for treating anxiety. pmc.ncbi.nlm.nih.gov